Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Common Equity: 2009-2024

Historic Common Equity for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $154.0 million.

  • Anika Therapeutics' Common Equity fell 18.38% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 18.38%. This contributed to the annual value of $154.0 million for FY2024, which is 27.45% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Common Equity is $154.0 million, which was down 27.45% from $212.3 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Common Equity registered a high of $287.1 million during FY2021, and its lowest value of $154.0 million during FY2024.
  • Its 3-year average for Common Equity is $217.3 million, with a median of $212.3 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first increased by 5.39% in 2021, then declined by 27.45% in 2024.
  • Anika Therapeutics' Common Equity (Yearly) stood at $272.4 million in 2020, then increased by 5.39% to $287.1 million in 2021, then fell by 0.53% to $285.6 million in 2022, then declined by 25.67% to $212.3 million in 2023, then fell by 27.45% to $154.0 million in 2024.